Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Papaverine and SBRT for NSCLC or Lung Metastases
NCT03824327Phase 1Active, not recruiting
- Sponsor
- The Ohio State University Comprehensive Cancer Center – James Cancer Hospital
- Start
- Feb 2019
- Primary completion
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of papaverine in non-small cell lung cancer (NSCLC) and lung metastases (LM), sponsored by The Ohio State University Comprehensive Cancer Center – James Cancer Hospital. Primary endpoint: Maximum-tolerated dose at 2 weeks. Started Feb 2019; status: active, not recruiting.
02
Drugs
papaverine
03
Conditions
non-small cell lung cancer (NSCLC)lung metastases (LM)
Beyond the preview
Go deeper on NCT03824327.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03824327.